LeMaitre Vascular Inc. (NASDAQ:LMAT) disclosed a series of insider transactions by Trent G. Kamke, the company's Senior Vice President of Operations. According to a Form 4 filing with the U.S. Securities and Exchange Commission, Kamke sold 1,044 shares of common stock on February 27, 2026, at $110.29 per share, yielding $115,142.
The sale occurred while the stock was trading near its 52-week high of $115.33, following an 18% price gain over the previous week. Shares of LeMaitre Vascular are up 32% year-to-date, and, per InvestingPro analysis cited in the filing, currently appear overvalued relative to their Fair Value.
The filing also indicates a separate disposition on February 26, 2026, when Kamke sold 93 shares at $113.69 to satisfy tax-withholding obligations tied to equity compensation. That sale produced proceeds of $10,573.
In the same period, Kamke received stock related to prior incentive awards. On settlement of a Performance Share Unit (PSU) award originally granted on December 6, 2024, he acquired 1,051 shares of LeMaitre Vascular common stock. He also received two additional shares upon the release of dividend equivalent rights.
LeMaitre Vascular is identified in the filing and accompanying materials as a $2.44 billion medical device company. The insider transactions come on the heels of the company reporting fourth-quarter 2025 financial results that topped analyst expectations.
For the fourth quarter, LeMaitre reported adjusted earnings per share of $0.68, above the $0.66 consensus estimate. Revenue for the quarter reached $64.45 million, exceeding the $62.98 million forecast.
Following the quarterly release, Citizens adjusted its price target on LeMaitre shares to $118 from $113 and kept a Market Outperform rating. Citizens analyst Daniel Stauder emphasized the company’s new fiscal 2026 adjusted EPS guidance of approximately $2.91, noting it meaningfully exceeded the consensus estimate of $2.58 - a roughly 13% uplift relative to consensus.
These entries in Kamke’s Form 4 reflect a mix of routine equity-compensation settlement and discretionary selling. The filings document both the liquidity event tied to the sale of 1,044 shares and the contemporaneous acquisition of shares through vesting and dividend equivalents.
Investors tracking insider behavior, valuation signals, and recent operational results may view these disclosures alongside the company’s stronger-than-expected quarter and raised guidance when assessing LeMaitre Vascular’s near-term outlook.